| Name | Title | Contact Details |
|---|---|---|
Ryan Hulslander |
Vice President, General Counsel | Profile |
Brett Mull |
Assistant General Counsel | Profile |
At Neopenda, we believe that the most vulnerable patient populations in the world deserve access to high quality health care. We re a social enterprise startup passionate about improving newborn health through innovative technology solutions, and implementing them sustainably in emerging markets. Neopendas first product is a scalable wireless vital signs monitor for patients in overcrowded, understaffed health facilities. Our solution reduces response time to newborns in distress, and helps healthcare workers to save more lives. We are currently validating our technology in clinical studies with our partners in Uganda.
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists` clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry.
At Enclear Therapies, our mission is to halt the progression of disease and extend the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP) by removing toxic proteins that build up in the brain, significantly impacting neurodegeneration.
High Technology is a Walpole, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With more than a 60-year history of pioneering products to treat millions of patients, Cordis is a worldwide leader in the development and manufacturing of interventional cardiovascular technology. Cordis established a legacy of high-quality and minimally-invasive cardiovascular products; and has built a robust global footprint with operations in more than 60 countries around the world. As from August 2, 2021, Cordis is a standalone company, and is committed to investing $300 million to accelerate innovation in its broad product portfolio. Building on our storied brand, we are unleashing our potential to be a $10 billion leader bringing new technology to the market through bold action at speed.